Cemsidomide

Cemsidomide is an orally bioavailable MonoDAC® degrader (or monofunctional degradation activating compound) designed to be highly potent and selective against its intended targets of Ikaros (IKZF1) and Aiolos (IKZF3) and overcome shortcomings of currently approved therapies to treat multiple myeloma and non-Hodgkin’s lymphoma. Initial clinical data show cemsidomide is well tolerated, demonstrates anti-myeloma activity and displays evidence of immunomodulatory effects.

Opportunity for Targeted Protein Degradation

IKZF1/3 are transcription factors required for cancer cell growth and survival in multiple myeloma and non-Hodgkin’s lymphomas. However, transcription factors do not have an active site binding pocket; this means inhibitors cannot target these important proteins. Rather, degraders are the only therapeutic approach. Today, approved IKZF1/3 degraders (lenalidomide and pomalidomide) are widely used in multiple myeloma treatment, but there remains a high unmet medical need for therapies to treat relapsed/refractory multiple myeloma.

Scientific Presentations and Publications

CFT7455, a novel IKZF1/3 degrader, enhances the anti-myeloma activity of monoclonal and bispecific antibodies by augmenting immune responses

CFT7455: A novel IKZF1/3 degrader, demonstrates potent anti-tumor activity in peripheral and CNS models of non-Hodgkin’s lymphoma as a single agent or in combination with clinically approved agents

The Discovery and Characterization of CFT7455: A Potent and Selective Degrader of IKZF1/3 for the Treatment of Relapsed/Refractory Multiple Myeloma

AACR Poster Presentation: CFT7455 Phase 1/2 Cohort A

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

CFT7455: A novel, IKZF1/3 Degrader That Demonstrates Potent Tumor Regression in a Spectrum of Non-Hodgkin Lymphoma Xenograft Models

CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models